BNET Industries
Cortex Pharmaceuticals Inc. (COR) is in the Pharma Industry
- Profit
- Dec 31 2007
- ($12.9M)
- Market Cap
- Aug 27 2008
- $44.2M
Latest News and Analysis
Cortex's AMPAKINE Molecule CX717 Has Positive Effects in Opiate-Induced Respiratory Depression in a Phase IIa Clinical Study
Correlation with Animal Studies Demonstrates AMPAKINE Compounds Can Prevent Opiate-Induced Respiratory Depression IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR) reported that top-line data from its first Phase IIa study in opiate-induced respiratory depression RD demonstrated that a single oral dose of 2100mg of AMPAKINE[R] CX717 achieved statistical...
*Revised* Analyst Reports for Cortex Pharmaceuticals Inc., Seabridge Gold Inc., Anooraq Resources Corporation, and Cano Petroleum Inc.
MaybachFinancial.com is one of the fastest growingindependent and unbiased research firms in the world. Through our numerouspartnerships with many of the top investment minds in the world, we provideresearch on companies making a move in the markets. Investors seekinggenuine analyst opinions on their investments for Cortex PharmaceuticalsInc. (AMEX: COR), Seabridge...
Cortex to Provide Top Line Data for CX717 Clinical Trial for the Prevention of Opiate-Induced Respiratory Depression in Humans
Presentation to be given at the Bank of Montreal's Focus on Healthcare Conference on August 5-6, 2008 IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com) Chairman, President and CEO, Roger G. Stoll, PhD, will speak at the Bank of Montreal's Focus on Healthcare Conference taking place August...
Neuro Sector Reviewed by NeuroInvestment
NeuroInvestment today announced the release ofits July/August issue, which overviews the CNS sector at midyear, andpreviews the second half of 2008. The major news at midyear was theAlzheimer's data which came from high-profile programs at Elan/Wyeth and atMyriad Genetics. The issue takes a hard look at those results,...
Cortex and Top Alberta Government Officials Meet to Discuss Progress on AMPAKINE Compounds at the 2008 Bio Conference
Joint Efforts Enabled AMPAKINE[R] CX717 to Move from Animals to Completing the First Two Phase II Clinical Studies in 13 Months SAN DIEGO -- Cortex Pharmaceuticals, Inc.'s (AMEX: COR) senior management is scheduled to have a 90 minute breakfast meeting hosted by the Alberta's Premier...
Cortex Pharmaceuticals Announces Management Changes
Mark Varney to Become President and Chief Executive Officer in August 2008 and Roger Stoll to Move to Executive Chairman of the Board IRVINE, Calif. -- Cortex Pharmaceuticals, Inc.'s (AMEX: COR) Dr. Roger Stoll, Chairman, President & CEO, announced at the company's Annual Shareholder Meeting that the Board...
Cortex Annual Shareholder Meeting Notification
IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com/), a neuroscience company focused on developing novel AMPAKINE([R]) drug therapies for psychiatric disorders, neurological diseases, and drug induced respiratory depression, will web cast presentations from its annual shareholder meeting scheduled for Wednesday, May 14, 2008, at 10:30 a.m. PDT (1:30 p.m....
Cortex Reports First Quarter Operating Results
IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com) reported a net loss of $4,371,000, or $0.09 per share for the quarter ended March 31, 2008 compared with a net loss of $3,884,000, or $0.10 per share for the corresponding prior year period. Non-cash stock-based compensation charges for the quarters...
Cortex Initiates Enrollment in Opiate Induced Respiratory Depression Clinical Trial in Germany Today
Goal is to Determine If CX717 Can Prevent Respiratory Depression without Affecting Analgesic Properties of Opiates IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com), was notified by the German regulatory agency which approves the use of narcotic drugs that it can proceed with the trial which will...
Cortex Reports Fourth Quarter and Year End Operating Results
IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com) reported a net loss of $3,273,000, or $0.07 per share for the quarter ended December 31, 2007 compared with a net loss of $3,462,000, or $0.10 per share for the corresponding prior year period. Non-cash stock-based compensation charges for the quarters...
Cortex Receives Approval from German Regulatory Authority to Proceed with Two Clinical Trials for AMPAKINE® CX717 for the Acute Treatment of Respiratory Depression Due to Opiate Analgesics
CX717 Does Not Affect the Analgesic Properties of Opiates IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com), has received approval from the German Federal Institute For Drugs And Medical Devices BfArM to initiate two AMPAKINE[R] CX717 clinical studies. These studies will assess whether the pre-administration of CX717...
Cortex's CEO to Present at the Roth Capital Partners 20th Annual Orange County Conference
Dana Point, California, Tuesday, February 19, 2008 IRVINE, Calif. -- First graph, first sentence should read: Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com), Chairman, President and CEO, Roger G. Stoll, PhD, will speak at the 20th Annual Roth Capital Partners Growth Stock Conference to be held at The Ritz-Carlton...
Cortex's CEO Roger Stoll to Speak at the Bank of Montreal's Focus on Healthcare Conference
Event to be Held at New York City's Millennium Broadway Hotel December 4-5, 2007 IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com) Chairman, President and CEO, Roger G. Stoll, PhD, will speak at the Bank of Montreal's Focus on Healthcare Conference taking place December...
Cortex Reports Third Quarter Operating Results
IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com) reported a net loss of $2,962,000, or $0.07 per share for the quarter ended September 30, 2007 compared with a net loss of $3,635,000, or $0.10 per share for the corresponding prior year period. Non-cash stock-based compensation charges...
Cortex's CEO to Present at Rodman & Renshaw's Ninth Annual Healthcare Conference On November 5, 2007
IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR) Chairman, President and CEO, Roger G. Stoll, Ph.D., will present at Rodman & Renshaw's Ninth Annual Healthcare Conference taking place November 5 - 7, 2007, at the New York Palace Hotel. Dr. Stoll will give the Company presentation on...
Cortex to Provide Shareholder Update and Host Conference Call on October 31, 2007
Cortex's AMPAKINE[R] Technology Featured in November, 2007 National Geographic Magazine Focused on Memory IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR) will host a conference call on Wednesday, October 31, 2007 at 12:00 Noon EDT (9:00 AM PDT) to discuss the recently announced decision by...
JMP Securities Healthcare Focus Conference to Be Held in Boston
SAN FRANCISCO -- JMP Group Inc. (NYSE:JMP), a growth-oriented investment banking and asset management firm, announced today that JMP Securities, JMP Group's broker-dealer subsidiary, will host the second annual JMP Securities Healthcare Focus Conference in Boston at the Four Seasons Hotel on Tuesday, November 13, 2007. ...
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
IRVINE, Calif. -- Cortex Pharmaceuticals, Inc (AMEX: COR) has named Pierre Tran, MD, MMM as its Chief Medical Officer and Vice President of Clinical Development. Dr. Tran will join the company's expert team as they continue development of the AMPAKINE[R] technology. Along with advancing the clinical development...
FDA's Psychiatric Division Has Rejected Cortex's Request to Study CX717 in Phase IIb ADHD Study
-- Company plans to focus on Alzheimer's disease PET scan study and the treatment of acute respiratory depression with CX717 -- IRVINE, Calif. -- Cortex Pharmaceuticals, Inc (AMEX:COR) was informed on Wednesday, October 10, 2007, that the Food and Drug Administration FDA would soon be...
Cortex to Provide Shareholder Update and Host Conference Call on September 19, 2007
IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX: COR) will host a conference call on Wednesday, September 19, 2007 at 4:00 PM EDT (1:00 PM PDT) to update shareholders on recent clinical, regulatory, and research activities related to their AMPAKINE([R]) technology platform and to discuss relevant financial, patent and business development...
- Next »
- page 1 of 1
- « Previous
- Incorporated: 1987
- CEO: Dr. Roger G. Stoll Ph.D.
- Employees: 27
Cortex Pharmaceuticals is engaged in developing drug-like compounds that positively modulate AMPA-type glutamate receptors, a complex of proteins involved in the communication between nerve cells in the mammalian brain. These compounds, termed A MPAKINE® compounds, enhance the activity of the AMPA receptor. As of Dec 31 2006, Co. owned or had exclusive rights within its areas of product development to more than 50 issued or allowed U.S. and foreign patents and had a number of additional U.S. patent applications and their international counterparts pending.
Key Competitors
Cortex Pharmaceuticals Inc. Company Info
Board of Directors
Dr. Roger G. Stoll Ph.D.
Chairman
Mr. Robert F. Allnutt
Mr. John F. Benedik
Mr. Charles J. Casamento
Dr. Carl W. Cotman Ph.D.
Dr. Peter F. Drake Ph.D.
Dr. M. Ross Johnson Ph.D.
Dr. Gary D. Tollefson M.D., Ph
Contact Information
15241 Barranca Parkway
Irvine, CA
949 727 3157
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
